



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾										
BABY CARE										
US	105	104	1.0%	1.0%	-	315	306	2.9%	2.9%	-
Intl	508	462	10.0%	4.8%	5.2%	1,457	1,326	9.9%	4.4%	5.5%
WW	613	566	8.3%	4.1%	4.2%	1,772	1,632	8.6%	4.1%	4.5%
ORAL CARE										
US	162	164	-1.2%	-1.2%	-	483	486	-0.6%	-0.6%	-
Intl	260	220	18.2%	11.1%	7.1%	729	651	12.0%	4.8%	7.2%
WW	422	384	9.9%	5.8%	4.1%	1,212	1,137	6.6%	2.5%	4.1%
OTC/NUTRITIONALS										
US	332	438	-24.2%	-24.2%	-	1,059	1,472	-28.1%	-28.1%	-
Intl	722	671	7.6%	0.3%	7.3%	2,207	1,985	11.2%	3.9%	7.3%
WW	1,054	1,109	-5.0%	-9.4%	4.4%	3,266	3,457	-5.5%	-9.7%	4.2%
SKIN CARE										
US	376	311	20.9%	20.9%	-	1,251	1,185	5.6%	5.6%	-
Intl	567	489	16.0%	8.4%	7.6%	1,520	1,378	10.3%	3.7%	6.6%
WW	943	800	17.9%	13.2%	4.7%	2,771	2,563	8.1%	4.5%	3.6%
WOMEN'S HEALTH										
US	104	121	-14.0%	-14.0%	-	350	404	-13.4%	-13.4%	-
Intl	354	338	4.7%	-1.6%	6.3%	1,044	990	5.5%	-0.5%	6.0%
WW	458	459	-0.2%	-4.8%	4.6%	1,394	1,394	0.0%	-4.3%	4.3%
WOUND CARE/OTHER										
US	140	139	0.7%	0.7%	-	445	447	-0.4%	-0.4%	-
Intl	110	110	0.0%	-8.2%	8.2%	355	350	1.4%	-5.5%	6.9%
WW	250	249	0.4%	-2.8%	3.2%	800	797	0.4%	-2.7%	3.1%
TOTAL CONSUMER										
US	1,219	1,277	-4.5%	-4.5%	-	3,903	4,300	-9.2%	-9.2%	-
Intl	2,521	2,290	10.1%	3.3%	6.8%	7,312	6,680	9.5%	2.9%	6.6%
WW	3,740	3,567	4.9%	0.5%	4.4%	11,215	10,980	2.1%	-1.9%	4.0%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ⁽²⁾⁽⁴⁾										
<u>ACIPHEX/PARIET</u>										
US	94	116	-19.0%	-19.0%	-	304	356	-14.6%	-14.6%	-
Intl	141	124	13.7%	3.9%	9.8%	417	398	4.8%	-2.8%	7.6%
WW	235	240	-2.1%	-7.2%	5.1%	721	754	-4.4%	-8.4%	4.0%
<u>CONCERTA/METHYLPHENIDATE</u>										
US	179	214	-16.4%	-16.4%	-	667	668	-0.1%	-0.1%	-
Intl	104	85	22.4%	13.7%	8.7%	327	283	15.5%	7.5%	8.0%
WW	283	299	-5.4%	-7.9%	2.5%	994	951	4.5%	2.1%	2.4%
<u>DOXIL/CAELYX</u>										
US	10	75	-86.7%	-86.7%	-	130	225	-42.2%	-42.2%	-
Intl	76	10	*	*	7.9%	233	28	*	*	7.3%
WW	86	85	1.2%	-6.1%	7.3%	363	253	43.5%	36.8%	6.7%
<u>DURAGESIC/FENTANYL TRANSDERMAL</u>										
US	31	42	-26.2%	-26.2%	-	69	117	-41.0%	-41.0%	-
Intl	124	142	-12.7%	-20.1%	7.4%	380	435	-12.6%	-19.5%	6.9%
WW	155	184	-15.8%	-21.5%	5.7%	449	552	-18.7%	-24.2%	5.5%
<u>LEVAQUIN/FLOXIN</u>										
US	14	274	-94.9%	-94.9%	-	585	926	-36.8%	-36.8%	-
Intl	11	12	-8.3%	-10.7%	2.4%	33	31	6.5%	2.7%	3.8%
WW	25	286	-91.3%	-91.4%	0.1%	618	957	-35.4%	-35.5%	0.1%
<u>PREZISTA</u>										
US	132	102	29.4%	29.4%	-	386	290	33.1%	33.1%	-
Intl	184	128	43.8%	36.2%	7.6%	509	331	53.8%	47.1%	6.7%
WW	316	230	37.4%	31.2%	6.2%	895	621	44.1%	38.7%	5.4%
<u>PROCIT/EPREX</u>										
US	176	204	-13.7%	-13.7%	-	623	800	-22.1%	-22.1%	-
Intl	207	202	2.5%	-5.4%	7.9%	632	655	-3.5%	-9.8%	6.3%
WW	383	406	-5.7%	-9.6%	3.9%	1,255	1,455	-13.7%	-16.5%	2.8%
<u>REMICADE</u>										
US	876	857	2.2%	2.2%	-	2,500	2,420	3.3%	3.3%	-
US Exports ⁽³⁾	343	365	-6.0%	-6.0%	-	1,360	1,106	23.0%	23.0%	-
Intl	189	7	*	*	6.3%	204	19	*	*	6.9%
WW	1,408	1,229	14.6%	13.6%	1.0%	4,064	3,545	14.6%	14.2%	0.4%
<u>RISPERDAL/RISPERIDONE</u>										
US	8	(2)	-	-	-	27	(14)	-	-	-
Intl	120	123	-2.4%	-9.7%	7.3%	367	390	-5.9%	-12.9%	7.0%
WW	128	121	5.8%	-1.7%	7.5%	394	376	4.8%	-2.5%	7.3%
<u>RISPERDAL CONSTA</u>										
US	111	108	2.8%	2.8%	-	335	340	-1.5%	-1.5%	-
Intl	279	270	3.3%	-4.8%	8.1%	863	772	11.8%	4.1%	7.7%
WW	390	378	3.2%	-2.6%	5.8%	1,198	1,112	7.7%	2.4%	5.3%
<u>TOPAMAX</u>										
US	45	46	-2.2%	-2.2%	-	136	162	-16.0%	-16.0%	-
Intl	72	81	-11.1%	-17.4%	6.3%	231	255	-9.4%	-14.9%	5.5%
WW	117	127	-7.9%	-11.9%	4.0%	367	417	-12.0%	-15.4%	3.4%
<u>VELCADE</u>										
US	-	-	-	-	-	-	-	-	-	-
Intl	295	246	19.9%	11.5%	8.4%	922	793	16.3%	9.1%	7.2%
WW	295	246	19.9%	11.5%	8.4%	922	793	16.3%	9.1%	7.2%
<u>OTHER</u>										
US	850	653	30.2%	30.2%	-	2,377	1,974	20.4%	20.4%	-
Intl	1,311	1,011	29.7%	21.3%	8.4%	3,657	2,926	25.0%	17.4%	7.6%
WW	2,161	1,664	29.9%	24.8%	5.1%	6,034	4,900	23.1%	18.5%	4.6%
TOTAL PHARMACEUTICAL										
US	2,869	3,054	-6.1%	-6.1%	-	9,499	9,370	1.4%	1.4%	-
Intl	3,113	2,441	27.5%	18.5%	9.0%	8,775	7,316	19.9%	12.1%	7.8%
WW	5,982	5,495	8.9%	4.9%	4.0%	18,274	16,686	9.5%	6.1%	3.4%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

**MAJOR NEW PHARM PRODUCTS ⁽⁴⁾
(INCLUDED IN OTHER)**

INTELENCE

	THIRD QUARTER		
	2011	2010	Total % Change
US	42	30	40.0%
Intl	41	37	10.8%
WW	83	67	23.9%

	NINE MONTHS		
	2011	2010	Total % Change
	118	93	26.9%
	113	85	32.9%
	231	178	29.8%

INVEGA

	THIRD QUARTER		
	2011	2010	Total % Change
US	74	63	17.5%
Intl	52	35	48.6%
WW	126	98	28.6%

	NINE MONTHS		
	2011	2010	Total % Change
	219	200	9.5%
	155	108	43.5%
	374	308	21.4%

SIMPONI

	THIRD QUARTER		
	2011	2010	Total % Change
US	59	51	15.7%
Intl	70	9	*
WW	129	60	*

	NINE MONTHS		
	2011	2010	Total % Change
	173	137	26.3%
	118	24	*
	291	161	80.7%

STELARA

	THIRD QUARTER		
	2011	2010	Total % Change
US	112	62	80.6%
Intl	77	38	*
WW	189	100	89.0%

	NINE MONTHS		
	2011	2010	Total % Change
	317	167	89.8%
	214	106	*
	531	273	94.5%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	THIRD QUARTER					NINE MONTHS				
	2011	2010	% Change			2011	2010	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS (2)										
<u>CARDIOVASCULAR CARE (5)</u>										
US	198	246	-19.5%	-19.5%	-	650	762	-14.7%	-14.7%	-
Intl	328	350	-6.3%	-13.5%	7.2%	1,098	1,161	-5.4%	-11.9%	6.5%
WW	526	596	-11.7%	-15.9%	4.2%	1,748	1,923	-9.1%	-13.1%	4.0%
<u>DEPUY</u>										
US	737	748	-1.5%	-1.5%	-	2,318	2,338	-0.9%	-0.9%	-
Intl	647	561	15.3%	6.0%	9.3%	2,038	1,800	13.2%	4.7%	8.5%
WW	1,384	1,309	5.7%	1.7%	4.0%	4,356	4,138	5.3%	1.6%	3.7%
<u>DIABETES CARE</u>										
US	338	338	0.0%	0.0%	-	982	941	4.4%	4.4%	-
Intl	326	275	18.5%	9.8%	8.7%	1,000	885	13.0%	6.1%	6.9%
WW	664	613	8.3%	4.4%	3.9%	1,982	1,826	8.5%	5.2%	3.3%
<u>ETHICON</u>										
US	519	480	8.1%	8.1%	-	1,575	1,499	5.1%	5.1%	-
Intl	668	592	12.8%	5.0%	7.8%	2,062	1,852	11.3%	4.1%	7.2%
WW	1,187	1,072	10.7%	6.4%	4.3%	3,637	3,351	8.5%	4.5%	4.0%
<u>ETHICON ENDO-SURGERY</u>										
US	472	484	-2.5%	-2.5%	-	1,433	1,474	-2.8%	-2.8%	-
Intl	759	653	16.2%	7.6%	8.6%	2,314	2,027	14.2%	6.4%	7.8%
WW	1,231	1,137	8.3%	3.4%	4.9%	3,747	3,501	7.0%	2.5%	4.5%
<u>ORTHO-CLINICAL DIAGNOSTICS</u>										
US	265	263	0.8%	0.8%	-	811	815	-0.5%	-0.5%	-
Intl	274	235	16.6%	8.7%	7.9%	799	702	13.8%	6.4%	7.4%
WW	539	498	8.2%	4.5%	3.7%	1,610	1,517	6.1%	2.7%	3.4%
<u>VISION CARE</u>										
US	251	241	4.1%	4.1%	-	752	722	4.2%	4.2%	-
Intl	501	454	10.4%	1.7%	8.7%	1,454	1,299	11.9%	3.1%	8.8%
WW	752	695	8.2%	2.5%	5.7%	2,206	2,021	9.2%	3.6%	5.6%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS										
US	2,780	2,800	-0.7%	-0.7%	-	8,521	8,551	-0.4%	-0.4%	-
Intl	3,503	3,120	12.3%	3.9%	8.4%	10,765	9,726	10.7%	3.0%	7.7%
WW	6,283	5,920	6.1%	1.7%	4.4%	19,286	18,277	5.5%	1.4%	4.1%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure

(5) Previously Cordis